gyki 52466 has been researched along with Alzheimer Disease in 1 studies
GYKI 52466: an AMPA (non-NMDA) receptor antagonist; structure given in first source
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Scriabine, A | 1 |
1 other study available for gyki 52466 and Alzheimer Disease
| Article | Year |
|---|---|
The Neurobiology and Neuropharmacology of Alzheimer's Disease. The ASPET - Ray Fuller Symposium. New Orleans, LA, USA, April 19-20, 2002.
Topics: Alzheimer Disease; Animals; Anti-Anxiety Agents; Benzodiazepines; Benzothiadiazines; Humans; Neurobi | 2002 |